Corvus Pharmaceuticals, Inc. 8-K

What Happened

• On January 20, 2026, Corvus Pharmaceuticals, Inc. (CRVS) notified Jefferies LLC that it has suspended the planned at-the-market (ATM) offering of its common stock under the prospectus supplement originally filed August 6, 2024.
• The ATM program was established under the Company’s shelf Registration Statement on Form S-3 (File No. 333-281318) and the Open Market Sale Agreement dated August 6, 2024.

Key Details

• The Sale Agreement covered up to $100 million of common stock available for sale.
• Prior to the suspension, no ATM shares had been sold; the full $100 million remained available.
• The Company will not make any sales under the Sale Agreement unless and until a new prospectus supplement or registration statement is filed with the SEC.
• The Sale Agreement remains in full force and effect despite the suspension.

Why It Matters

• For investors, this means Corvus is pausing a potential source of equity capital that could have diluted existing shareholders; however, no dilution occurred because no ATM sales were made.
• The suspension could reflect the company’s decision to delay raising funds via this vehicle until market, regulatory or timing conditions change; Corvus may restart sales only after filing new offering documentation with the SEC.
• The filing is procedural (Item 8.01) and contains forward-looking statement disclosures; it is not an offering or solicitation of securities.